Let's see whats new in the market
Teledyne FLIR, part of Teledyne Technologies Incorporated, announced it has won a contract to develop the first mass-wearable chemical detector for U.S. troops under the Pentagon’s Compact Vapor Chemical Agent Detector (CVCAD) program. The company received $4.0 million in initial funding. The new, lightweight CVCAD sensor will provide the benefit of individual protection for every warfighter, particularly all U.S. Soldiers and Marines conducting ground operations.
Kromek is pleased to announce that it has been awarded a new $6m contract by the Defense Advanced Research Projects Agency (“DARPA”), for Phase II of its development of a biological threat detection system that senses, analyses and identifies airborne pathogens. Kromek will deliver the contract over the next 28-month period, commencing immediately. Phases I and II are an extension of the existing SIGMA network for biological threats as part of DARPA’s SIGMA+ initiative.
Emergent BioSolutions Inc. announced that two batches of COVID-19 vaccine manufactured by Emergent BioSolutions at its Baltimore Bayview facility were determined to be suitable for use by the U.S. Food & Drug Administration (FDA) and have been authorized as part of Johnson & Johnson’s Emergency Use Authorization (EUA). Emergent is actively addressing issues identified by the FDA at its Bayview facility and plans to resume manufacturing of the Johnson & Johnson COVID-19 vaccine drug substance.
Following the second conciliation protocol signed on May 21, 2021 with its creditors, CNIM Group announces the closing of the divestment of the IT activities of its subsidiary Bertin Technologies, comprising Bertin IT and Vecsys, to ChapsVision. This transaction was announced in the press release published by CNIM Group on February 17, 2021. These divestments are part of the measures provided for in the conciliation protocol and are intended to partially repay CNIM Group's medium-term debt. Bertin IT and Vecsys specialize in the edition and integration of software solutions for cybersecurity, digital intelligence, business intelligence and speech processing.
908 Devices a pioneer of mass spectrometry devices for chemical and biomolecular analysis, has appointed Marcia Eisenberg, Ph.D to serve on its Board of Directors effective immediately. Dr. Eisenberg has extensive experience with forensic DNA testing, biotechnology, molecular genetics and molecular oncology. She has helped lead the development and validation of well over a thousand clinical assays used for patient care during her more than 30-year tenure at Labcorp, a global life sciences company.
Thermo Fisher Scientific today introduced the Ion AmpliSeq SARS-CoV-2 Insight Research Assay to improve SARS-CoV-2 surveillance. The assay is designed to enable early identification of new and known variants from samples that have lower viral loads. By sequencing more than 99 percent of the SARS-CoV-2 genome, the assay covers all potential serotypes. The new Ion AmpliSeq SARS-CoV-2 Insight Research Assay broadens and improves local, regional and national surveillance efforts to discover emerging SARS-CoV-2 variants through highly sensitive next-generation sequencing (NGS).
Agilent Technologies Inc. (NYSE: A) today announced the release of Sure Select Human All Exon V8 – a new exome design that provides comprehensive content and up-to-date coverage of protein-coding regions from RefSeq, CCDS, and GENCODE. It also covers the TERT promoter and hard-to-capture exons that are omitted by other exomes on the market. The new design is available in three options – routine exome sequencing (Exome v8), clinical research sequencing (v8 Clinical Plus), and translational research (v8 UTR Plus) – allowing for content flexibility to meet our customer’s needs.
The FLIR identiFINDER R700 Backpack Radiation Detector (BRD) offers new spectroscopic broad-search capabilities. Once dismounted, the identiFINDER R700 provides the capabilities required to successfully perform wide-area searches quickly and efficiently while offering exceptional sensitivity, communication, and trusted spectroscopic algorithms in a lightweight, ergonomic form-factor.
At Bruker’s virtual 4D-Proteomics™ eXceed Symposium, Bruker Corporation announced the launch of two new timsTOF instruments. They further advance and enable new applications and methods in unbiased proteomics, epiproteomics/PTM characterization, and unbiased, deep multiomic biomarker discovery, for example in cancer liquid biopsy research. Bruker’s collaborators are making major progress in unbiased single cell proteomics, phosphoproteomics and plasma proteomics, leveraging the speed, sensitivity and dynamic range of large-scale CCS-enabled 4D-Proteomics and 4D-Epiproteomics.
The 4030 ELITE Suit and Helmet System is designed in collaboration with EOD operators and is tested in accordance with NIJ 0117.01*, the US National Institute of Justice Public Safety Bomb Suit standard. It introduces a new approach to EOD protection, delivering superior survivability and enhanced ergonomics at a reduced weight, along with a user configurable and scalable platform. The certification to the NIJ Standard is still in process.